Loading organizations...
§ Private Profile · Kitchener, ON, Canada
Medical device company, AI-driven monitoring platforms for post-operative patient care, enabling early complication identification.
Based in Kitchener-Waterloo, Ontario, FluidAI Medical develops artificial intelligence-driven monitoring platforms and sensors designed to manage and improve post-operative patient care. The medical technology enterprise provides hardware and software solutions, including the Origin inline sensing system and the Stream Care suite, which capture real-time data from surgical sites to help hospitals identify complications earlier. Targeting a domestic market of over 3.5 million annual general and gastrointestinal surgeries in the United States, the medical device manufacturer has raised $17.5 million in total venture funding to date. This capital includes a $15 million Series A financing round backed by lead investors SOSV and Graphene Ventures, supporting the commercialization of its technology following recent 510(k) clearance from the FDA. Originally operating under the name NERv Technology, FluidAI Medical was founded in 2014 by Youssef Helwa and Amr Abdelgawad.
FluidAI Medical has raised $18.8M across 3 funding rounds.
FluidAI Medical has raised $18.8M in total across 3 funding rounds.
FluidAI Medical has raised $18.8M in total across 3 funding rounds.
FluidAI Medical's investors include SOSV, Nabil Alnoor Borhanu, Boutique Venture Partners, Cur8 Capital, Juno Pharmaceuticals, Kyto Technology & Life Science, Leva Capital, ThresholdImpact, Graphene Ventures, NorthSpring Capital Partners, OneValley Ventures, Sunhope Venture Capital.
FluidAI Medical has raised $18.8M across 3 funding rounds. Most recently, it raised $15.0M Series A in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2022 | $15M Series A | SOSV, Nabil Alnoor Borhanu | Boutique Venture Partners, Cur8 Capital, Juno Pharmaceuticals, Kyto Technology & Life Science, Leva Capital, Thresholdimpact | Announced |
| Apr 1, 2020 | $3M Seed | SOSV | Boutique Venture Partners, Graphene Ventures, Northspring Capital Partners, OneValley Ventures, Thresholdimpact | Announced |
| Oct 16, 2019 | $760K Pre Seed | Sunhope Venture Capital | — | Announced |
FluidAI Medical is a Canadian medtech company founded in 2014 (formerly NERv Technology) that develops AI-driven platforms for postoperative surgical care, focusing on general and gastrointestinal surgeries.[1][2][3] Its flagship product, Origin, is an inline sensing device that connects to surgical drains to monitor effluent in real-time for early detection of complications like leaks and infections, integrating with the AI-powered Stream Care suite for predictive analytics and decision support.[2][5] Serving hospitals and clinicians, FluidAI addresses postoperative risks by combining proprietary sensors, EHR data, and AI to enable proactive interventions, reducing complications, hospital stays, and costs—having raised $20.25M total, with recent FDA 510(k) clearance in September 2025 marking strong growth momentum.[2][3][5]
FluidAI Medical originated in Kitchener, Ontario, Canada, in 2014 as NERv Technology, initially supported by HAX accelerator for prototyping and industrial design to reach its first product iteration.[2][4] The idea stemmed from harnessing AI and sensors to analyze surgical drain fluid for early complication detection, validated through animal trials that demonstrated feasibility and led to a 2019 pre-seed raise.[4] Pivotal moments include rebranding to FluidAI, building a multidisciplinary team of clinicians, engineers, and data scientists, amassing one of the world's largest surgical datasets, and securing FDA clearance for Origin in 2025, enabling U.S. market entry and integration with broader platforms.[1][4][5]
FluidAI rides the wave of AI-enabled precision medicine and proactive postoperative monitoring, capitalizing on surging demand for data-driven healthcare amid rising surgical volumes and complication costs (e.g., infections prolonging stays).[1][5] Timing aligns with post-pandemic emphasis on efficiency, EHR digitization, and regulatory tailwinds like FDA clearance, amid market forces favoring interoperable medtech that cuts readmissions by 20-30% via early detection.[5] It influences the ecosystem by pioneering effluent-based biomarkers, partnering with hospitals/academics for research, and building dataset "banks" to expand beyond GI/general surgery—setting standards for AI-surgical integration and enabling scalable, value-based care models.[4][6]
FluidAI is poised for U.S. commercialization post-FDA nod, with Stream Care-Origin integration accelerating pilots and revenue as hospitals prioritize complication reduction.[5] Trends like multimodal AI, biomarker expansion, and nanotechnology will shape its path toward broader indications (e.g., cardiology, oncology), leveraging its dataset moat for new monitoring paradigms.[4] Influence may evolve into a platform leader, powering ecosystem-wide digital surgery via partnerships—transforming reactive recovery into proactive, personalized care and redefining medtech impact from Kitchener to global health systems.[1][6]